Pegfilgrastim is a long-acting G-CSF that has been shown to reduce the risk of FN by 94% with first-cycle use in patients with breast cancer receiving docetaxel 100 mg/m2 every 3 weeks [9, 11]. Here, CSF3 is linked to breast cancer.